ELISA, Western Blotting (WB), Immunofluorescence (IF), Immunocytochemistry (ICC)
Purification
PLAC1 Antibody is affinity chromatography purified via peptide column.
Immunogen
PLAC1 antibody was raised against a 15 amino acid synthetic peptide near the carboxy terminus of human PLAC1. The immunogen is located within amino acids 130 - 180 of PLAC1.
PLAC1
Reactivity: Human
ELISA
Host: Rabbit
Polyclonal
FITC
Application Notes
PLAC1 antibody can be used for detection of PLAC1 by Western blot at 1 μ,g/mL. Antibody can also be used for immunocytochemistry starting at 10 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
PLAC1 Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
PLAC1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CT92 antibody, DXWsu72e antibody, Epcs26 antibody, placenta specific 1 antibody, placenta-specific 1 antibody, placental specific protein 1 antibody, PLAC1 antibody, Plac1 antibody
Background
PLAC1 Antibody: PLAC1 was initially identified as a protein expressed specifically in the placenta and other cells derived from the trophoblast lineage during embryonic development, but has also been found to be expressed ectopically in a wide range of human malignancies, particularly breast cancers. PLAC1 is a membrane-associated protein that is thought to serve a receptor-like function modulating cell-cell or ligand receptor interactions unique to the maternal-placental interface. Decreased expression of PLAC1 is associated with decreased expression of cyclin D1 and reduced expression of AKT kinase, which, combined with the fact that PLAC1 is expressed on the surface of cancer cells, suggests that PLAC1 may be an effective candidate for immunotherapeutic treatments of cancer.